GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OWC Pharmaceutical Research OWCP · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 26 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2018

Revenue

—

FY2014FY2018

Net income

−$10.3m

FY2014FY2018

Free cash flow

−$2.5m

FY2014FY2018

Shareholders' equity

−$9.4m

FY2014FY2018

Income statement

Fiscal years

FY2018FY2017FY2016FY2015FY2014
Revenue——$50,000——
Gross profit−$7,000−$8,000$40,314−$9,123—
Research and development$712,000$441,203$141,858$271,394$160,325
Operating income−$4.3m−$4.6m−$2.1m−$1.7m−$5.0m
Net income−$10.3m−$4.6m−$2.3m−$1.7m−$5.1m
Diluted earnings per share-0.03-2.29-0.01-0.02-0.09

Balance sheet

At each fiscal year end

FY2018FY2017FY2016FY2015FY2014
Total assets$3.6m$1.1m$496,768$430,448$1.5m
Cash and short-term investments$3.5m$970,542$472,282$357,161$1.5m
Total liabilities$13.0m$270,485$395,780$107,626$60,304
Debt——$250,000$3,074—
Shareholders' equity−$9.4m$790,598$100,988$322,822$1.5m
Shares outstanding400m2m166m81m59m

Cash flow

Fiscal years

FY2018FY2017FY2016FY2015FY2014
Cash from operations−$2.5m−$1.2m−$529,269−$1.2m−$602,404
Capital spending−$28,000−$9,511−$1,860−$2,569−$32,194
Free cash flow−$2.5m−$1.2m−$531,129−$1.2m−$634,598

Latest quarters

By quarter end

Sept 2019Jun 2019Mar 2019Dec 2018Sept 2018Jun 2018Mar 2018Dec 2017
Operating income−$889,000−$9.1m−$568,000−$957,425−$669,042−$968,018−$976,514−$13,089
Net income−$287,000$7.7m−$1.0m−$5.1m−$991,094−$3.2m−$977,139−$13,110
Diluted earnings per share-0.000.03-0.00-0.01-0.00-0.01-0.00-0.01
Total assets$1.8m$2.3m$2.9m$3.6m$4.3m$4.8m$736,146$9,419
Cash and short-term investments$1.5m$1.8m$2.8m—$4.2m$4.6m$691,558—
Debt$26,000$26,000$26,000—————
Shareholders' equity−$4.0m−$3.0m−$10.2m−$9.4m−$3.8m−$2.2m$501,674$7,018

Valuation history

At each fiscal year end

FY2016
Price to sales0.0

Share price return

Finished calendar years

202420232022202120202019201820172016
Return-90%100%20700%-73%579%-91%-65%239%15985%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 26 Oct 2012
  • 3-for-1 split · 13 Feb 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.